Show simple item record

dc.contributor.authorPathmanathan, AU
dc.contributor.authorAlexander, EJ
dc.contributor.authorHuddart, RA
dc.contributor.authorTree, AC
dc.date.accessioned2017-03-01T12:54:00Z
dc.date.issued2016-11
dc.identifier.citationFuture oncology (London, England), 2016, 12 (21), pp. 2495 - 2511
dc.identifier.issn1479-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/450
dc.identifier.eissn1744-8301
dc.identifier.doi10.2217/fon-2016-0129
dc.description.abstractDose escalation to the prostate improves tumor control but at the expense of increased rectal toxicity. Modern imaging can be used to detect the most common site of recurrence, the intraprostatic lesion (IPL), which has led to the concept of focusing dose escalation to the IPL in order to improve the therapeutic ratio. Imaging must be able to detect lesions with adequate sensitivity and specificity to accurately delineate the IPL. This information must be carefully integrated into the radiotherapy planning process to ensure the dose is targeted to the IPL. This review will consider the role and challenges of multiparametric MRI and PET computed tomography in delineating a tumor boost to be delivered by external beam radiotherapy.
dc.formatPrint-Electronic
dc.format.extent2495 - 2511
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectMagnetic Resonance Imaging
dc.subjectNeoplasm Staging
dc.subjectRadiotherapy Dosage
dc.subjectRadiotherapy Planning, Computer-Assisted
dc.subjectReproducibility of Results
dc.subjectMale
dc.subjectMultimodal Imaging
dc.subjectPositron Emission Tomography Computed Tomography
dc.titleThe delineation of intraprostatic boost regions for radiotherapy using multimodality imaging.
dc.typeJournal Article
dcterms.dateAccepted2016-05-01
rioxxterms.versionofrecord10.2217/fon-2016-0129
rioxxterms.licenseref.urihttps://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfFuture oncology (London, England)
pubs.issue21
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublished
pubs.volume12
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten
dc.contributor.icrauthorTree, Alisonen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record